Treatment of experimental periodontal disease by a selective inhibitor of cyclooxygenase-2 with scaling and root planing (SRP).
Lumiracoxib is a selective inhibitor of cyclooxygenase-2 (COX-2) approved for the relief of symptoms of chronic inflammatory conditions. The aim of this study was to evaluate the effects of this specific inhibitor of COX-2 as adjunctive treatment on induced periodontitis in rats. Periodontal disease was induced at the first mandibular molar of 60 rats. After 7 days, the ligature was removed and all animals were submitted to scaling and root planing (SRP) along with local irrigation with saline solution and were divided into 2 groups: SRP (n = 30)-received subcutaneous injections of 1 mg/kg of body weight/day of saline solution for 3 days and; SRP + L (n = 30)-received subcutaneous injections of 1 mg/kg of body weight/day of Lumiracoxib for 3 days. Ten animals in each group were killed at 7, 15, and 30 days. The histological description was performed and the histometric values were statistically analyzed. In Group SRP + L, the histometric analysis (0.58 ± 0.08, 0.64 ± 0.06, and 0.56 ± 0.10 mm(2)) showed less bone loss (p < 0.05) than Group SRP (1.52 ± 0.08, 1.55 ± 0.09, and 1.49 ± 0.24 mm(2)) at 7, 15, and 30 days, respectively. Within the limits of this study it can be concluded that subcutaneous application of specific inhibitor of COX-2 was a beneficial adjunctive treatment for periodontal diseases induced in rats.
GEPLO, Group of Research and Study on Laser in Dentistry, Department of Surgery and Integrated Clinic, Division of Periodontics, Univ Estadual Paulista, Araçatuba, São Paulo, Brazil.
Valdir Gouveia
VG
Garcia
Rodrigo Yuji
RY
Takano
Leandro Araújo
LA
Fernandes
Juliano Milanezi
JM
de Almeida
Leticia Helena
LH
Theodoro
D016301:Alveolar Bone Loss / Q000628:therapy; D000818:Animals; D017024:Chemotherapy, Adjuvant; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D012534:Dental Scaling; D004008:Diclofenac / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D008297:Male; D010518:Periodontitis / Q000628:therapy*; D051381:Rats; D017208:Rats, Wistar; D016745:Root Planing
D052246:Cyclooxygenase 2 Inhibitors; D004008:Diclofenac; C473384:lumiracoxib